Another Botox Competitor: Revance Prepares Longer-Lasting RT002 For BLA Submission
Executive Summary
A claim that RT002's duration of efficacy surpasses the leading neurotoxin – Allergan's blockbuster Botox – will be put to the test when Revance seeks US FDA approval to treat frown lines in the first half of this year. The company's Botox biosimilar with Mylan also could move forward in 2019.
You may also be interested in...
Revance's Daxxify Is Approved As Rival To Botox With Longer Efficacy
The company is preparing a staged launch for the neuromodulator in the aesthetics market, with a focus on educating select dermatologists first before expanding to 4,000 physician partners.
J.P. Morgan Notebook Day 4: Novartis CEO Weighs In On AI, Sangamo’s Next Steps And More
Additional highlights from the J.P. Morgan Healthcare Conference, including Takeda’s partnering outlook, Sage’s guidance on Zulresso sales, Frequency’s next steps for its hearing loss drug and Revance’s preparations to take on the aesthetics market.
J.P. Morgan Notebook Day 4: Novartis CEO Weighs In On AI, Sangamo’s Next Steps And More
Additional highlights from the J.P. Morgan Healthcare Conference, including Takeda’s partnering outlook, Sage’s guidance on Zulresso sales, Frequency’s next steps for its hearing loss drug and Revance’s preparations to take on the aesthetics market.